Stacey M Stein MD
Cancer Genetics/Cancer Risk Assessment, Gastrointestinal Cancer
Associate Professor of Medicine, Rutgers Cancer Institute, System Leader Med Onc Hepatobiliary Cancer RWJB Network
Join to View Full Profile
165 Somerset StreetNew Brunswick, NJ 08901
Dr. Stein is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Stacey Stein is a medical oncologist focused on treating patients with GI cancers. She is based in New Brunswick, NJ and completed a fellowship in Hematology and Medical Oncology at the NYU Grossman School of Medicine in 2010, having graduated from Rutgers Robert Wood Johnson Medical School in 2004. Dr. Stein has significant experience dealing with conditions such as liver cancer, biliary cancer, pancreatic cancer, colon cancer. A published author, her research covers a range of cancer-related topics and her work has been cited in other publications. Dr. Stein has been involved in a number of clinical trials.
Education & Training
NYU Grossman School of MedicineFellowship, Hematology and Medical Oncology, 2007 - 2010
Montefiore Medical Center/Albert Einstein College of Medicine (Moses and Weiler Campuses)Residency, Internal Medicine, 2004 - 2007
Rutgers Robert Wood Johnson Medical SchoolClass of 2004
Certifications & Licensure
NJ State Medical License 2024 - 2027
CT State Medical License 2010 - 2025
NY State Medical License 2007 - 2010
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2013-2014, 2016-2017
Clinical Trials
- Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery Start of enrollment: 2009 Oct 28
- Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery Start of enrollment: 2014 Feb 01
- Cetuximab and Savolitinib Treatment of Ras Wild-Type Colorectal Cancer Start of enrollment: 2017 Jan 01
Publications & Presentations
PubMed
- 2 citationsBiliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology.Al B Benson 3rd, Michael I D'Angelica, Thomas Abrams, Aijaz Ahmed, Mehmet Akce
Journal of the National Comprehensive Cancer Network. 2025-09-01 - Are all programmed cell death protein 1 inhibitors the same?Jochen H Lorch, Stacey Stein, Martin J Edelman
Frontiers in Oncology. 2025-01-01 - 3 citationsTumor response assessment in hepatocellular carcinoma treated with immunotherapy: imaging biomarkers for clinical decision-making.Rabea Sobirey, Nickolai Matuschewski, Moritz Gross, MingDe Lin, Tabea Kao
European Radiology. 2025-01-01
Lectures
- Association of real-world agreement between HER2 expression and ERBB2 amplification with trastuzumab therapy benefit in advanced gastric/esophageal (adv GE) cancer pat...ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/23/2020
- Safety and clinical activity of 1L atezolizumab + bevacizumab in a phase Ib study in hepatocellular carcinoma (HCC).2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
Press Mentions
Dr. Stacey Stein and Dr. Neal Fischbach Appointed as Assistant Medical Directors at Yale Cancer Center Clinical Trials OfficeOctober 15th, 2021
New Investigation into PD-1 Blockade for Hepatocellular CarcinomaJanuary 10th, 2020
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
